Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On June 8, 2020, as described below, the stockholders of Vaxart, Inc. (“Vaxart” or the “Company”) approved the amendment to the Vaxart, Inc. 2019 Equity Incentive Plan (as so amended, the “Amended Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 6,400,000 shares to 8,000,000 shares.
As previously disclosed, the Amended Plan authorizes the grant of equity-based compensation to the Company’s employees, directors and consultants, and provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property.
A description of the material terms of the Amended Plan was included in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2020 (the “2020 Proxy Statement”). In addition, the foregoing description of the Amended Plan is qualified in its entirety by reference to the text of the Amended Plan, which will be filed with the Company’s next periodic report.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) on June 8, 2020 at 385 Oyster Point Boulevard, Suite 9A, South San Francisco, California 94080. At the 2020 Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the 2020 Proxy Statement. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the 2020 Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.
Proposal 1. Stockholders elected the seven nominees for directors to serve until Vaxart’s 2021 Annual Meeting of Stockholders or until his respective successor has been duly elected and qualified. The voting results were as follows:
Director Name
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Wouter Latour, M.D.
|
|
|
33,842,198
|
|
|
|
238,288
|
|
|
|
22,551,920
|
|
Steven Boyd
|
|
|
33,546,744
|
|
|
|
533,682
|
|
|
|
22,551,920
|
|
Todd C. Davis
|
|
|
33,181,392
|
|
|
|
899,034
|
|
|
|
22,551,920
|
|
Michael J. Finney
|
|
|
30,397,420
|
|
|
|
3,863,006
|
|
|
|
22,551,920
|
|
Andrei Floroiu
|
|
|
33,724,248
|
|
|
|
356,178
|
|
|
|
22,551,920
|
|
Keith Maher, M.D.
|
|
|
33,655,583
|
|
|
|
424,843
|
|
|
|
22,551,920
|
|
Robert A. Yedid
|
|
|
32,919,705
|
|
|
|
1,160,721
|
|
|
|
22,551,920
|
|
Proposal 2. Stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to (i) increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares and (ii) decrease the par value of the Company’s capital stock from $0.10 per share to $0.0001 per share. The voting results were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
45,691,728
|
|
9,739,391
|
|
1,201,227
|
|
—
|
Proposal 3. Stockholders approved the amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance thereunder by 6,400,000 to 8,000,000 shares. The voting results were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
28,617,314
|
|
5,326,840
|
|
136,272
|
|
22,551,920
|
Proposal 4. Stockholders ratified the selection of OUM & Co. LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020. The voting results were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
54,955,793
|
|
829,715
|
|
846,838
|
|
—
|
Proposal 5. Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement. The voting results were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
32,880,270
|
|
745,928
|
|
454,228
|
|
22,551,920
|
Item 8.01. Other Events.
On June 8, 2020, the Company and Armistice Capital Master Fund, Ltd. (“Armistice”) entered into amendments (the “Warrant Amendments”) to (i) the Common Stock Purchase Warrant, issued as of April 11, 2019, to purchase 4,090,909 shares of common stock of the Company, par value $0.10 per share (“Common Stock”; such warrant, the “$1.10 Warrant”), and (ii) the Common Stock Purchase Warrant, issued as of September 30, 2019, to purchase 16,666,667 shares of Common Stock (the “$0.30 Warrant”; together with the $1.10 Warrant, the “Original Warrants”), each of which is held by Armistice.
Each of the Warrant Amendments increases the beneficial ownership limitation in those instruments from 4.99%, in the case of the $1.10 Warrant, and 9.99%, in the case of the $0.30 Warrant, to 19.99% in each. The Warrant Amendments also remove the requirement to provide 60 days’ notice to the Company of an increase in the beneficial ownership limitation. All other terms of the Original Warrants will remain in full force and effect.
The foregoing description of the Warrant Amendments is qualified in its entirety by reference to the copies thereof to be filed as an exhibit to the next periodic report of the Company.